liraglutide 3 mg / Generic mfg. - LARVOL DELTA

Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026. (PubMed, Pediatrics) - "In this cohort of >3.5 million children aged 8 to 11 with obesity and without diabetes, GLP-1RA prescribing increased sharply from 2019 to 2026 yet remained uncommon, reaching 0.6% of children. Clinicians appear to be reserving GLP-1RAs for those at greatest cardiometabolic risk. Prescriptions are more likely to go to those with less socioeconomic vulnerability."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics

Changes in cardiovascular, mental-health and inflammation-related medication use following initiation of a GLP-1 receptor agonist: a real-world Irish pharmacy study (EASD 2026) - "Adults with at least one dispensed prescription of a GLP-1 RA indicated for obesity management (liraglutide 3.0 mg) were included if they had ≥6 months of continuous treatment and ≥12 months of pharmacy history before and after initiation. In this real-world analysis of Irish pharmacy dispensing data, initiation of a GLP-1 receptor agonist for obesity management was associated with reduced dispensing of cardiovascular, mental health, and inflammation-related medicines after at least six months of treatment. These findings may reflect changes in treatment patterns or clinical management following obesity pharmacotherapy. Further prospective studies incorporating clinical outcomes are warranted to better understand the mechanisms and implications of these observed changes."

Clinical • Real-world • Real-world evidence • Metabolic Disorders • Obesity

One year of exercise improves testosterone levels in males with obesity with effects maintained one-year after treatment compared with liraglutide: a randomised controlled trial (EASD 2026) - P4 | "Following an initial 8-week low-calorie diet, participants were randomised to one year of moderate-to-vigorous exercise, liraglutide 3.0 mg/day, the combination, or placebo. One year of exercise increased free testosterone levels which was maintained, whereas liraglutide had no effect on free testosterone. At a one year follow up improvements were sustained in the males assigned to exercise compared with liraglutide. Thus, exercise has independent and beneficial effects on testosterone in males with obesity, highlighting its importance beyond weight loss alone or pharmacologically weight reduction with liraglutide."

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - P3 | N=183 | Completed | Sponsor: Beni-Suef University | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Obesity • Polyendocrine Metabolic Ovarian Syndrome

Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. (PubMed, J Endocrinol Invest) - "GLP-1 and GLP-1/GIP receptor agonists produce clinically meaningful weight loss vs. placebo over ≥ 1 year. Semaglutide 7.2 mg consistently ranks above 2.4 mg, but the average incremental benefit (~ 2-3% points) appears modest and should be interpreted in the context of limited statistically significant differences between doses, as well as balanced against considerations of tolerability and patient preferences. Further head-to-head trials and real world studies are warranted to refine dose selection and long-term safety."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants. (PubMed, Obes Pillars) - "Liraglutide 3.0 mg and semaglutide 2.4 mg represent high-cost non-governmental retail scenarios rather than expected institutional procurement estimates. Extended-release naltrexone/bupropion provides a lower-cost non-GLP-1 comparator,and extended-release phentermine/topiramate was analyzed only as an exploratory supplementary comparator."

HEOR • Journal • Genetic Disorders • Obesity

Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "Subgroup analysis by drug class yielded: semaglutide 2.4 mg, 7.19% (k = 6; 95% CI: 6.42-7.96); liraglutide 3.0 mg, 4.83% (k = 4; 95% CI: 3.87-5.79); and tirzepatide, 13.04% (k = 3; 95% CI: 11.87-14.21). The magnitude of regain tracks initial efficacy and supports a long-term pharmacotherapy model analogous to chronic disease management. Future trials should pre-specify post-cessation follow-up as a mandatory outcome."

Journal • Retrospective data • Review • Genetic Disorders

The medicines regulator has issued a new safety warning for GLP-1-based drugs, like Ozempic, which could potentially cause a rare, but serious eye disorder (ABC News) - "The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists which are used to treat type 2 diabetes and obesity: (i) Semaglutide, sold as Ozempic, Wegovy; (ii) Tirzepatide, sold as Mounjaro; (iii) Dulaglutide, sold as Trulicity; (iv) Liraglutide, sold as Saxenda. The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)."

Adverse events • Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery. (PubMed, Obes Surg) - "Early liraglutide initiation, particularly at six months post-surgery, was linked to greater weight loss and more favourable metabolic profiles compared with standard care. These findings suggest that timely pharmacotherapy may be associated with improved long-term weight management outcomes, though causality remains to be established."

Journal • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025. (PubMed, Mil Med) - "In this large cohort of ADSMs, Zepbound and Wegovy were associated with substantially higher persistence and adherence compared to Saxenda. These findings have important implications for clinical decision-making and formulary management to optimize long-term outcomes for weight management."

Journal

Comparative Accuracy of Large Language Models in Providing Clinical Information on Anti-Obesity Medications (ENDO 2026) - "Materials and A total of 120 standardized clinical prompts (40 per medication: Saxenda, Wegovy, and Mounjaro) were evaluated across ChatGPT, Gemini, Meta AI, and Copilot. While generative AI shows potential as a supplementary tool, it currently lacks the necessary reliability for independent clinical use in obesity management. The high incidence of inaccurate responses necessitates that healthcare providers and patients continue to rely strictly on validated clinical guidelines and manufacturer documentation to ensure safe medication practices."

Clinical • Genetic Disorders • Obesity

GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety. (PubMed, Diabetes Res Clin Pract) - "Childhood obesity and youth-onset type 2 diabetes mellitus (T2DM) are increasing, highlighting the need for effective treatments beyond lifestyle intervention and metformin...In youth-onset T2DM, liraglutide 1.8 mg/day and dulaglutide significantly improved HbA1c compared with placebo...No significant adverse effects on linear growth or pubertal progression were reported. GLP-1 RAs are effective adjuncts for pediatric obesity and T2DM, but longer-term studies are needed to assess cardiovascular safety, bone health, and growth outcomes."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 2 Diabetes Mellitus

Blood Pressure and Weight Outcomes Following First-Time Use of GLP-1 Therapies in Adults with Diabetes (ENDO 2026) - "Adults with diabetes starting FDA-approved GLP-1 therapies for weight management (Saxenda®, Wegovy®, Zepbound®) with at least six months of data before and after treatment initiation were included... In adults with diabetes, systolic blood pressure changes did not significantly differ by GLP-1 therapy selection after adjusting for weight loss. Our results suggest that weight change is the primary driver of systolic blood pressure changes."

Clinical • Diabetes • Metabolic Disorders

Lipase Elevation with Glucagon-Like Peptide-1 Receptor Agonist - to Treat or Not to Treat? (ENDO 2026) - "In the SCALE trials, only 2.9% of patients on liraglutide 3.0mg had lipase elevations of ≥3x ULN compared to 1.5% on placebo. In conclusion, this case reinforces that isolated, even marked, lipase elevation during GLP-1 RA therapy may not mandate drug discontinuation in the absence of symptoms or imaging evidence of pancreatitis. Clinicians should avoid routine pancreatic enzyme testing in asymptomatic patients and focus on symptom-based evaluation."

Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hepatology • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Mood Disorders • Nephrology • Obesity • Obstructive Sleep Apnea • Pancreatitis • Renal Disease • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

Severe Pediatric Obesity with Suspected Genetic Etiology: Outcomes and Barriers after 18 Months of Glucagon-Like Peptide-1 Receptor Agonist Therapy (ENDO 2026) - "GLP-1RA therapy (liraglutide 3.0 mg/day, then semaglutide titrated to 1.75 mg/week) stopped the weight-gain trajectory. GLP-1RA therapy produced clinically meaningful and sustained improvements across anthropometric, metabolic, and functional domains in a case of extreme pediatric obesity with a probable genetic etiology. Key teaching points include: early recognition of features suggestive of genetic obesity syndrome, consideration of incretin-based therapy for extreme pediatric phenotypes, and addressing socioeconomic barriers as integral components of long-term obesity management - an unmet need in vulnerable populations."

Clinical • Late-breaking abstract • Cardiovascular • Developmental Disorders • Dyslipidemia • Genetic Disorders • Hidradenitis Suppurativa • Hypertension • Immunology • Mental Retardation • Obesity • Obstructive Sleep Apnea • Pediatrics • Prader–Willi syndrome • Respiratory Diseases • Sarcopenia • Sleep Disorder

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes (clinicaltrials.gov) - P=N/A | N=125000 | Enrolling by invitation | Sponsor: Indiana University

HEOR • New trial • Genetic Disorders • Obesity

Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials (ADA 2026) - "We wanted to systematically study the impact on adverse events. We conducted a meta-analysis of randomized, placebo-controlled trials evaluating liraglutide 3 mg once daily, semaglutide 2.4 mg once weekly, and tirzepatide 15 mg once weekly in adults with overweight or obesity. Marked and significant differences in weight-reducing efficacy exist among incretin-based therapies, whereas risks of gastrointestinal AE, treatment discontinuation, and hypoglycemia are broadly comparable, likely reflecting dose-escalation strategies that improve tolerability."

Retrospective data • Hypoglycemia • Metabolic Disorders • Obesity

Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa. (PubMed, Clin Infect Dis) - "This trial is among the first studies of GLP-1 RAs in Southern Africa and demonstrates that this class for obesity treatment among PWH in this region has efficacy to improve metabolic health and that the study intervention was acceptable in this population."

Journal • CNS Disorders • Depression • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity • Psychiatry

Positive recommendations on new hybrid medicines (European Medicines Agency) - "Treatment of diabetes and weight management...Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise."

CHMP • Obesity • Type 2 Diabetes Mellitus

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. (PubMed, Endocrinol Diabetes Metab) - "Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials."

Clinical • Journal • Retrospective data • Review • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity

A nationwide analysis of pharmacological treatment of obesity – Patient characteristics and real-world drug utilization patterns (ECO 2026) - " We analysed data from the Norwegian Prescribed Drug Registry from 2016 to September 2024 and described incident use of naltrexone/ bupropion, orlistat, liraglutide 3.0 mg and semaglutide 2.4 mg, as well as the anti-diabetic drug semaglutide 1.0 mg commonly used off-label for weight-management. The rapid uptake of semaglutide 2.4 mg has markedly reshaped the Norwegian OMM landscape. Despite predominantly self-funded treatment, users of semaglutide 2.4 mg share similar characteristics with other OMM users. Real-world use is characterized by initiation at non-recommended doses, treatment interruptions and click-counting, which may have important effects on persistence and real-world treatment outcomes."

Clinical • Real-world • Real-world evidence • Genetic Disorders • Obesity

Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity (clinicaltrials.gov) - P4 | N=30 | Active, not recruiting | Sponsor: University of Sao Paulo General Hospital

New P4 trial • Cardiovascular • Genetic Disorders • Obesity

Resting energy expenditure and muscle strength are preserved after weight loss induced by liraglutide or naltrexonebupropion (ECO 2026) - " We performed a retrospective observational study in which we evaluated 72 adults with obesity treated with liraglutide 3.0 mg (n=47) or naltrexone-bupropion 32/360 mg (n=25). In adults with obesity, after 16 weeks of liraglutide or naltrexone-bupropion treatment significant weight loss was observed with preserved REE and muscle strength. This suggests a protective effect on REE and muscle quality by these second generation anti-obesity medicines. Conflicts of Interest: None Disclosed Funding: Research relating to this abstract was funded by Elisabeth Foundation (EFCvR), Netherlands Organization of Scientific Research NWO/ZONMW (NWO-Vidi to EFCvR: 91716453 and NWO-Veni to MRB: 09150161910073), Dutch Research Council and the Dutch Ministry of Education, Culture and Science (NWO gravitation grant 024.005.010 to EFCvR)."

Genetic Disorders • Obesity

Does sex matter when maintaining weight loss? Sex differences during weight loss maintenance with GLP-1-based therapy and exercise: a randomized controlled trial (ECO 2026) - P4 | "After an 8-week low-calorie diet, consisting of four meal replacement products per day (~800 kcal/ day), participants achieving ≥5% weight loss were randomized (1:1:1:1) to 52 weeks of placebo, GLP-1 RA treatment alone (liraglutide 3.0 mg s.c. daily), structured exercise alone, or liraglutide in combination with structured exercise (combination group). In this study, females had a larger percentage reduction in body weight and a larger reduction in HbA1c with GLP-1 RA treatment alone compared to males. In contrast, this study showed that males had larger improvements in fat-free mass and cardiorespiratory fitness with GLP-1 RA, exercise and the combination of the two compared to females. Both males and females improved their body composition in all three intervention groups during weight loss maintenance."

Clinical • Genetic Disorders • Obesity

Effects of Liraglutide therapy on mental health status of adolescents with morbid obesity (ECO 2026) - "Collectively, these preliminary findings indicate that liraglu-tide treatment in adolescents with morbid obesity may yield early psychological benefits, which subsequently diminish over time, yet demonstrate sustained improvement relative to the initial baseline. By offering rare early insights into the psychological outcomes of GLP-1 agonist treatment in this population, the study is likely to help address an important gap in the current literature. The ongoing collection of data will facilitate more robust longitudinal and comparative analyses."

CNS Disorders • Genetic Disorders • Obesity